We have seen the pharma-provider relationship and healthcare landscape continue to evolve in recent years. As the rate of oncology drug approvals increases, both through additional indications and new treatment innovations, ensuring oncology physicians and patients have access to the right education at the right time is essential to better care and outcomes.
Cancer treatment innovations increasing at a high rate
From 2014 to 2018 there have been 57 new oncology treatments approved across 89 indications. In 2018 alone, 15 oncology drugs were approved across 17 indications. New cancer drugs are being approved at a high rate and existing drugs are gaining multiple indications. That’s a lot of new information for oncologists and patients to track.
More cancer drug approvals create demand for targeted education
This fast rate of innovation in cancer therapies has created an increased demand to understand targeted therapies. Pharma companies have an opportunity make sure the right targeted messaging and information gets in front of the right audience at the right time.
Studies also show that patients want to be active participants and engaged in their treatment more than ever before. This makes it even more important for patients to have access to the right information before and during treatment.
Delivering tailored messaging to the right audience at the right time is essential
Navigating Cancer works with pharma companies to drive targeted physician and patient engagement. We offer solutions that can help provide the right engagement opportunities. Our targeted education is delivered to patients at the right moments in their treatment journey, including unbranded education at the time of diagnosis and branded education once treatment has begun.
Want to learn more or chat with a member of our pharmaceutical sales team? Contact us today to get started.